Cyproterone Acetate-Induced Acute Liver Failure: A Case Report and Review of the Literature

Pramod Kumar; Sujith Reddy; Anand Kulkarni; Mithun Sharma; Padaki N Rao

doi:10.1016/j.jceh.2021.01.003

Cyproterone Acetate-Induced Acute Liver Failure: A Case Report and Review of the Literature

J Clin Exp Hepatol. 2021 Nov-Dec;11(6):739-741. doi: 10.1016/j.jceh.2021.01.003. Epub 2021 Jan 27.

Authors

Pramod Kumar¹, Sujith Reddy¹, Anand Kulkarni¹, Mithun Sharma¹, Padaki N Rao¹

Affiliation

¹ Department of Hepatology and Liver Transplantation, Asian Institute of Gastroenterology Hospitals, Survey No 136, Mindspace Rd, Gachibowli, Hyderabad, Telangana 50003, India.

Abstract

Cyproterone acetate (CPA), a hydroxyprogesterone derivative, is used to treat advanced prostate cancer and infrequently in women for acne, breast cancer and hirsutism. Transient mild elevation in levels of liver enzymes is reported in 10-30% of patients, and acute liver failure (ALF) is uncommon. Here, we discuss the first case of CPA-induced ALF from India and the available literature.

Keywords: ALF, Acute liver failure; ALT, Alanine transaminase; CPA, Cyproterone acetate; DILI, Drug-induced liver injury; HAV, Hepatitis A virus; HBsAg, Hepatitis B surface antigen; HCV, Hepatitis C virus; HEV, Hepatitis E virus; MELD, Model for end-stage liver disease; RUCAM, Roussel Uclaf Causality Assessment Method; acute liver failure; cyproterone acetate; drug-induced liver injury.

Publication types

Case Reports